OBJECTIVES: Studies of HIV-associated brain atrophy often focus on a priori brain regions of interest, which can introduce bias. A data-driven, minimally biased approach was used to analyze changes in brain volumetrics associated with HIV and their relationship to aging, viral factors, combination antiretroviral therapy (cART), and gender, and smoking. DESIGN: A cross-sectional study of 51 HIV-uninfected (HIV-) and 146 HIV-infected (HIV+) participants. METHODS: Structural MRI of participants was analyzed using principal component analysis (PCA) to reduce dimensionality and determine topographies of volumetric changes. Neuropsychological (NP) assessment was examined using global and domain-specific scores. The effects of HIV disease factors (eg, viral load, CD4, etc.) on brain volumes and neuropsychological were investigated using penalized regression (LASSO). RESULTS: Two components of interest were visualized using principal component analysis. An aging effect predominated for both components. The first component, a cortically weighted topography, accounted for a majority of variance across participants (43.5% of variance) and showed independent effects of HIV and smoking. A secondary, subcortically weighted topography (4.6%) showed HIV-status accentuated age-related volume loss. In HIV+ patients, the cortical topography correlated with global neuropsychological scores and nadir CD4, whereas subcortical volume loss was associated with recent viral load. CONCLUSIONS: Cortical regions showed the most prominent volumetric changes because of aging and HIV. Within HIV+ participants, cortical volumes were associated with immune history, whereas subcortical changes correlated with current immune function. Cognitive function was primarily associated with cortical volume changes. Observed volumetric changes in chronic HIV+ patients may reflect both past infection history and current viral status.
OBJECTIVES: Studies of HIV-associated brain atrophy often focus on a priori brain regions of interest, which can introduce bias. A data-driven, minimally biased approach was used to analyze changes in brain volumetrics associated with HIV and their relationship to aging, viral factors, combination antiretroviral therapy (cART), and gender, and smoking. DESIGN: A cross-sectional study of 51 HIV-uninfected (HIV-) and 146 HIV-infected (HIV+) participants. METHODS: Structural MRI of participants was analyzed using principal component analysis (PCA) to reduce dimensionality and determine topographies of volumetric changes. Neuropsychological (NP) assessment was examined using global and domain-specific scores. The effects of HIV disease factors (eg, viral load, CD4, etc.) on brain volumes and neuropsychological were investigated using penalized regression (LASSO). RESULTS: Two components of interest were visualized using principal component analysis. An aging effect predominated for both components. The first component, a cortically weighted topography, accounted for a majority of variance across participants (43.5% of variance) and showed independent effects of HIV and smoking. A secondary, subcortically weighted topography (4.6%) showed HIV-status accentuated age-related volume loss. In HIV+ patients, the cortical topography correlated with global neuropsychological scores and nadirCD4, whereas subcortical volume loss was associated with recent viral load. CONCLUSIONS: Cortical regions showed the most prominent volumetric changes because of aging and HIV. Within HIV+ participants, cortical volumes were associated with immune history, whereas subcortical changes correlated with current immune function. Cognitive function was primarily associated with cortical volume changes. Observed volumetric changes in chronic HIV+ patients may reflect both past infection history and current viral status.
Authors: M A Cole; J B Margolick; C Cox; X Li; O A Selnes; E M Martin; J T Becker; H A Aronow; B Cohen; N Sacktor; E N Miller Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Mario Ortega; Jodi M Heaps; John Joska; Florin Vaida; Soraya Seedat; Dan J Stein; Robert Paul; Beau M Ances Journal: J Neurovirol Date: 2013-10 Impact factor: 2.643
Authors: Edgar Turner Overton; Tej D Azad; Neva Parker; Debra Demarco Shaw; Judy Frain; Teresa Spitz; Elizabeth Westerhaus; Robert Paul; David B Clifford; Beau M Ances Journal: J Neurovirol Date: 2013-01-24 Impact factor: 2.643
Authors: Kristina Crothers; Joseph L Goulet; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Matthew Bidwell Goetz; Stephen Crystal; David A Leaf; Adeel A Butt; R Scott Braithwaite; Robin Peck; Amy C Justice Journal: AIDS Educ Prev Date: 2009-06
Authors: Rhoda Au; Sudha Seshadri; Philip A Wolf; Merrill Elias; Penelope Elias; Lisa Sullivan; Alexa Beiser; Ralph B D'Agostino Journal: Exp Aging Res Date: 2004 Oct-Dec Impact factor: 1.645
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Ingjerd W Manner; Marius Trøseid; Olav Oektedalen; Morten Baekken; Ingrid Os Journal: J Clin Hypertens (Greenwich) Date: 2012-10-26 Impact factor: 3.738
Authors: Christina S Meade; Andrea L Hobkirk; Sheri L Towe; Nan-Kuei Chen; Ryan P Bell; Scott A Huettel Journal: Drug Alcohol Depend Date: 2017-07-08 Impact factor: 4.492
Authors: Andrew L Callen; Sara M Dupont; Jeffrey Pyne; Jason Talbott; Phyllis Tien; Evan Calabrese; David Saloner; Felicia C Chow; Jared Narvid Journal: J Neurovirol Date: 2020-06-04 Impact factor: 2.643
Authors: Katherine M Clifford; Vishal Samboju; Yann Cobigo; Benedetta Milanini; Gabriel A Marx; Joanna M Hellmuth; Howard J Rosen; Joel H Kramer; Isabel E Allen; Victor G Valcour Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Patrick Luckett; Robert H Paul; Jaimie Navid; Sarah A Cooley; Julie K Wisch; Anna H Boerwinkle; Dimitre Tomov; Beau M Ances Journal: J Acquir Immune Defic Syndr Date: 2019-12-15 Impact factor: 3.731